Rapid Disease Progression of Advanced Non-small Cell Lung Cancer Five Months after Cessation of Pembrolizumab

Atsuko Hirabae, Eiki Ichihara, Ryota Sunami, Moeko Ota, Yoshitaka Iwamoto, Yoshinobu Maeda, Katsuyuki Kiura

Research output: Contribution to journalArticlepeer-review

Abstract

We report a case of late-onset hyperprogressive disease after cessation of a PD-1 inhibitor. A male was diagnosed with metastatic lung adenocarcinoma with little progression for 2 months before treatment. He received pembrolizumab as a second-line treatment and was subsequently prescribed docetaxel for 3 months until a slight increase in pleural effusion. At the time of progression to docetaxel, he commenced prednisolone because of immune-system-related diarrhea. After that, his general condition rapidly worsened with severe fatigue and hypoxia. Computed tomography revealed a massive increase of pleural effusion and replacement of almost the entire liver with cancer over a period of 5 weeks.

Original languageEnglish
Pages (from-to)423-425
Number of pages3
JournalActa medica Okayama
Volume74
Issue number5
Publication statusPublished - 2020

Keywords

  • hyperprogression
  • immune checkpoint inhibitors
  • lung cancer
  • pembrolizumab

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'Rapid Disease Progression of Advanced Non-small Cell Lung Cancer Five Months after Cessation of Pembrolizumab'. Together they form a unique fingerprint.

Cite this